No Data
HUTCHMED (China) (LON:HCM) Shareholders Have Earned a 3.7% CAGR Over the Last Three Years
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
Hutchmed (China) (00013.HK): Completed patient enrollment for the Phase II registration study of HMPL-453 (fanregratinib) for the treatment of intrahepatic cholangiocarcinoma in China.
On March 6, Gelonghui announced that Hutchmed (China) (00013.HK) has completed patient enrollment for the phase II clinical trial of HMPL-453 (fanregratinib) for the treatment of intrahepatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements. This study is a single-arm, multicenter, open-label phase II registration study aimed at evaluating the efficacy, safety, and pharmacokinetics of HMPL-453 for the treatment of advanced intrahepatic cholangiocarcinoma patients with FGFR2 fusions/rearrangements. The primary endpoint of the study is the objective response rate (ORR). Secondary
HUTCHMED Completes Enrollment for Phase II Trial of Fanregratinib in Liver Cancer Patients
Express News | - HUTCHMED China Ltd - Completed Enrollment of Phase II Study
Express News | HUTCHMED Announces That It Has Completed Enrollment of a Phase II Registration Study of Fanregratinib (Hmpl-453) for Intrahepatic Cholangiocarcinoma in China
